

Hetty E Carraway

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115467/publications.pdf>

Version: 2024-02-01

225
papers

4,846
citations

117625

34
h-index

98798

67
g-index

226
all docs

226
docs citations

226
times ranked

7332
citing authors

#	ARTICLE	IF	CITATIONS
1	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. <i>Leukemia</i> , 2021, 35, 1023-1036.	7.2	62
2	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	1.3	5
3	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021, 35, 3324-3328.	7.2	2
4	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. <i>Blood</i> , 2021, 137, 3685-3689.	1.4	50
5	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	1.4	32
6	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , 2021, 6, .	5.0	12
7	Current and emerging strategies for management of myelodysplastic syndromes. <i>Blood Reviews</i> , 2021, 48, 100791.	5.7	34
8	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	1.2	3
9	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory) Tj ETQq1 1 0.784314 rg5T /Over	1.4	1
10	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia</i> , 2021, 35, 2431-2434.	7.2	10
11	Impact of next generation sequencing results on clinical management in patients with hematological disorders. <i>Leukemia and Lymphoma</i> , 2021, 62, 1702-1710.	1.3	4
12	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. <i>Blood</i> , 2021, 138, 3666-3666.	1.4	1
13	A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 786-786.	1.4	0
14	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 891-905.	0.9	0
15	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , 2020, 34, 957-962.	7.2	32
16	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , 2020, 34, 327-330.	7.2	3
17	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e98-e101.	3.5	23
18	Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. <i>Leukemia and Lymphoma</i> , 2020, 61, 1242-1245.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. British Journal of Haematology, 2020, 188, 924-929.	2.5	15
20	Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 70-77.	0.4	10
21	Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology, 2020, 11, 204062072095500.	2.5	19
22	Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci. Best Practice and Research in Clinical Haematology, 2020, 33, 101191.	1.7	6
23	Inherited Thrombocytopenia Caused by Germline <i>ANKRD26</i> Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962093894.	0.6	6
24	Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia. Scientific Reports, 2020, 10, 10325.	3.3	15
25	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leukemia Research, 2020, 91, 106339.	0.8	20
26	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. British Journal of Haematology, 2020, 189, 318-322.	2.5	10
27	Distinctive and common features of moderate aplastic anaemia. British Journal of Haematology, 2020, 189, 967-975.	2.5	10
28	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leukemia and Lymphoma, 2020, 61, 1943-1953.	1.3	2
29	The Clonal Trajectories of <i>SF3B1</i> Mutations in Myeloid Neoplasia. Blood, 2020, 136, 8-8.	1.4	1
30	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. Blood, 2020, 136, 2-2.	1.4	1
31	Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels. Blood, 2020, 136, 29-30.	1.4	4
32	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. Blood, 2020, 136, 1-1.	1.4	1
33	A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory <i>IDH2</i> mutant AML. Blood, 2020, 136, 28-29.	1.4	0
34	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. Blood, 2020, 136, 25-25.	1.4	0
35	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. Blood, 2020, 136, 28-28.	1.4	1
36	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. Blood, 2020, 136, 34-35.	1.4	0

#	ARTICLE	IF	CITATIONS
37	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. Blood, 2020, 136, 13-14.	1.4	2
38	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. Blood, 2020, 136, 21-21.	1.4	0
39	Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome. Blood, 2020, 136, 21-21.	1.4	1
40	The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. Leukemia, 2019, 33, 2971-2974.	7.2	32
41	Clonal Myeloid Events Drive Leukemic Evolution in Antecedent Hematologic Disorders. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S337.	0.4	0
42	The Road Less Travelled, from Large Granular Lymphocytic Leukemia to Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S345.	0.4	0
43	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 4231-4237.	7.0	30
44	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	5.2	34
45	When should transplant physicians think about familial blood cancers?. Advances in Cell and Gene Therapy, 2019, 2, e68.	0.9	4
46	Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels. JCO Precision Oncology, 2019, 3, 1-11.	3.0	6
47	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	1.4	66
48	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2696-2696.	1.4	1
49	FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults. Blood, 2019, 134, 452-452.	1.4	2
50	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. Blood, 2019, 134, 16-16.	1.4	2
51	Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.. Journal of Clinical Oncology, 2019, 37, 1507-1507.	1.6	3
52	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). Blood, 2019, 134, 1281-1281.	1.4	0
53	Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine. Blood, 2019, 134, 537-537.	1.4	0
54	Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS. Blood, 2019, 134, 881-881.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia. Blood, 2019, 134, 564-564.	1.4	0
56	Molecular Characterization of EP300 Mutant Myeloid Neoplasia. Blood, 2019, 134, 5043-5043.	1.4	0
57	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 1226-1226.	1.4	0
58	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. Blood, 2019, 134, 3743-3743.	1.4	0
59	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. Blood, 2019, 134, 381-381.	1.4	2
60	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. Blood, 2019, 134, 2595-2595.	1.4	1
61	Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia. Blood, 2019, 134, 2553-2553.	1.4	2
62	IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clinical Cancer Research, 2018, 24, 1705-1715.	7.0	80
63	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer Journal, 2018, 8, 4.	6.2	43
64	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. Leukemia and Lymphoma, 2018, 59, 363-371.	1.3	4
65	Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter. Journal of Clinical Oncology, 2018, 36, 3186-3188.	1.6	1
66	Reply to A. Piccardo et al, E. Hindi et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. Journal of Clinical Oncology, 2018, 36, 1889-1892.	1.6	3
67	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 1831-1839.	1.6	112
68	TP53 Mutations in Myeloid Neoplasms and Clonal Hematopoiesis of Indeterminate Potential following Cytotoxic Therapy for Antecedent Malignancy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S264.	0.4	0
69	Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S261.	0.4	0
70	Mutational Landscape of Therapy-Related Myeloid Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S263-S264.	0.4	1
71	Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes. Leukemia and Lymphoma, 2018, 59, 755-757.	1.3	6
72	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. Journal of Clinical Investigation, 2018, 128, 4260-4279.	8.2	97

#	ARTICLE	IF	CITATIONS
73	LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes. Blood, 2018, 132, 3073-3073.	1.4	2
74	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2018, 132, 1797-1797.	1.4	5
75	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. Blood, 2018, 132, 4806-4806.	1.4	1
76	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy. Blood, 2018, 132, 1389-1389.	1.4	1
77	Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential. Blood, 2018, 132, 3084-3084.	1.4	1
78	Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).. Journal of Clinical Oncology, 2018, 36, 7031-7031.	1.6	2
79	Abstract 1501: Developing novel strategy for the treatment of acute myeloid leukemia by targeting retinoic acid signaling pathways. , 2018, , .		0
80	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. Blood, 2018, 132, 2270-2270.	1.4	0
81	Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype. Blood, 2018, 132, 2809-2809.	1.4	0
82	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. Blood, 2018, 132, 4352-4352.	1.4	1
83	Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia. Blood, 2018, 132, 2590-2590.	1.4	0
84	Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2018, 132, 2583-2583.	1.4	0
85	Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML. Blood, 2018, 132, 4353-4353.	1.4	0
86	Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?. Blood, 2018, 132, 900-900.	1.4	0
87	Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. Blood, 2018, 132, 4389-4389.	1.4	1
88	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. Blood, 2018, 132, 2075-2075.	1.4	0
89	Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2018, 132, 4603-4603.	1.4	0
90	Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia. Blood, 2018, 132, 4067-4067.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies. <i>Blood</i> , 2018, 132, 211-211.	1.4	0
92	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. <i>Blood</i> , 2018, 132, 3074-3074.	1.4	0
93	Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States. <i>Blood</i> , 2018, 132, 2298-2298.	1.4	1
94	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1527-1527.	1.4	0
95	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018, 132, 371-371.	1.4	0
96	Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia. <i>Blood</i> , 2018, 132, 3869-3869.	1.4	0
97	Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis. <i>Blood</i> , 2018, 132, 4805-4805.	1.4	0
98	Molecular features of early onset adult myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1028-1034.	3.5	20
99	Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin lymphoma and Concurrent EBV, CMV, and Candida Infections. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961668451.	0.6	9
100	Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 60-87.	4.9	254
101	Emerging therapies for acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 93.	17.0	119
102	Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 183-198.	7.4	32
103	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. <i>Leukemia Research</i> , 2017, 61, 25-32.	0.8	12
104	A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. <i>British Journal of Haematology</i> , 2017, 176, 241-247.	2.5	23
105	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	7.0	56
106	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 899-907.	7.0	37
107	Hospital readmission rate for febrile neutropenia (FN) following high dose cytarabine (HiDAC) consolidation chemotherapy for acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, e18513-e18513.	1.6	0
108	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. <i>Blood</i> , 2017, 130, 878-878.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure. Hematology American Society of Hematology Education Program, 2016, 2016, 470-477.	2.5	12
110	Primary Care Physician Preferences and Perspectives on Long-Term Care of Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S85-S86.	2.0	3
111	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. Blood, 2016, 128, 1659-1659.	1.4	2
112	Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes. Blood, 2016, 128, 2002-2002.	1.4	1
113	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood, 2016, 128, 215-215.	1.4	25
114	Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. Blood, 2016, 128, 2786-2786.	1.4	2
115	U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. Blood, 2016, 128, 3155-3155.	1.4	5
116	Pathogenic Relevance of Germ Line TET2 Alterations. Blood, 2016, 128, 3160-3160.	1.4	2
117	Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. Blood, 2016, 128, 3892-3892.	1.4	2
118	Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials. Blood, 2016, 128, 4000-4000.	1.4	2
119	Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 4245-4245.	1.4	9
120	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. Blood, 2016, 128, 4301-4301.	1.4	2
121	Clinical Effects of IDH1/2-Mutant Inhibitors in IDH1/2-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Suggestions from Ex Vivo Experiments. Blood, 2016, 128, 4308-4308.	1.4	1
122	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy. Blood, 2016, 128, 447-447.	1.4	3
123	Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best. Blood, 2016, 128, 50-50.	1.4	5
124	Thirty-year analysis of randomized clinical trials in patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, 7032-7032.	1.6	0
125	Aldehyde Dehydrogenase Activity in the Leukemic Stem Cell Compartment Uncovers Opposing Methylation Patterns of Leukemia Stem Cells in AML. Blood, 2016, 128, 3925-3925.	1.4	0
126	Germline Variants of RUNX-1 in Myeloid Malignancy. Blood, 2016, 128, 3926-3926.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Targeting Autophagy in Myelodysplastic Syndromes. Blood, 2016, 128, 4295-4295.	1.4	1
128	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4065-4065.	1.4	0
129	UTX mutations in Myeloid Neoplasms. Blood, 2016, 128, 3148-3148.	1.4	0
130	Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms. Blood, 2016, 128, 2872-2872.	1.4	0
131	Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion. Blood, 2016, 128, 2007-2007.	1.4	5
132	Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms. Blood, 2016, 128, 4313-4313.	1.4	0
133	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. Blood, 2016, 128, 4293-4293.	1.4	0
134	Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response. Blood, 2016, 128, 1603-1603.	1.4	0
135	Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 3541-3541.	1.4	0
136	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. Blood, 2016, 128, 957-957.	1.4	0
137	Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals. Blood, 2016, 128, 2731-2731.	1.4	0
138	A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S195-S196.	0.4	0
139	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica, 2015, 100, e434-e437.	3.5	27
140	The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine. Clinical Cancer Research, 2015, 21, 439-447.	7.0	37
141	Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 292-297.	0.4	9
142	Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy. Blood, 2015, 126, 1319-1319.	1.4	2
143	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. Blood, 2015, 126, 1361-1361.	1.4	2
144	Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications. Blood, 2015, 126, 1647-1647.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). Blood, 2015, 126, 1697-1697.	1.4	2
146	Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis. Blood, 2015, 126, 2507-2507.	1.4	2
147	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. Blood, 2015, 126, 300-300.	1.4	3
148	Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia. Blood, 2015, 126, 3788-3788.	1.4	3
149	The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 607-607.	1.4	3
150	Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response. Blood, 2015, 126, 678-678.	1.4	6
151	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. Journal of Clinical Oncology, 2015, 33, 11047-11047.	1.6	1
152	Abstract 5575: Obesity and genomic changes in patients with myelodysplastic syndromes. , 2015, , .		0
153	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. Blood, 2015, 126, 1350-1350.	1.4	1
154	Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy. Blood, 2015, 126, 1271-1271.	1.4	0
155	Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia. Blood, 2015, 126, 2901-2901.	1.4	0
156	Whole-Exome Sequencing Identifies Germline IDH2 and IDH3 mutations That Predispose to Myeloid Neoplasms. Blood, 2015, 126, 1405-1405.	1.4	3
157	Next-Generation Bisulfite Sequencing of Aml Reveals Widespread Acquisition of Epigenetic Abnormalities in Leukemic Stem Cells That Are Stably Retained in More Mature Leukemic Cell Fractions. Blood, 2015, 126, 2429-2429.	1.4	0
158	Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012). Blood, 2015, 126, 4491-4491.	1.4	0
159	Characterization of the Mutational Spectrum in Young Patients with Myelodysplastic Syndrome. Blood, 2015, 126, 5218-5218.	1.4	0
160	The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML). Blood, 2015, 126, 86-86.	1.4	0
161	Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies. Blood, 2015, 126, 960-960.	1.4	0
162	Prognostic Impact of Molecular Mutations in AML at First Relapse. Blood, 2015, 126, 3825-3825.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 611-611.	1.4	0
164	Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2015, 126, 2127-2127.	1.4	1
165	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318.	2.0	103
166	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. <i>Blood</i> , 2014, 124, 385-392.	1.4	195
167	A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. <i>Haematologica</i> , 2014, 99, 672-678.	3.5	48
168	The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies. <i>Blood</i> , 2014, 124, 1897-1897.	1.4	1
169	Risk of hematologic malignancies following radiation treatment for well-differentiated thyroid cancer in the United States over 37 years.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6633-6633.	1.6	0
170	Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. <i>Blood</i> , 2014, 124, 1054-1054.	1.4	0
171	A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 168-168.	1.4	0
172	A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients. <i>Blood</i> , 2014, 124, 5252-5252.	1.4	0
173	Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 3274-3274.	1.4	4
174	Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 1933-1933.	1.4	0
175	Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5256-5256.	1.4	1
176	The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 979-979.	1.4	0
177	Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines. <i>Blood</i> , 2014, 124, 1290-1290.	1.4	0
178	Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2014, 124, 5266-5266.	1.4	0
179	Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4603-4603.	1.4	0
180	Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy. <i>Blood</i> , 2014, 124, 3766-3766.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS. Blood, 2014, 124, 3233-3233.	1.4	0
182	Multiple Mechanisms Leading to ARID2 defects in Myeloid Neoplasms. Blood, 2014, 124, 4610-4610.	1.4	0
183	Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. Blood, 2014, 124, 2279-2279.	1.4	0
184	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leukemia and Lymphoma, 2013, 54, 483-490.	1.3	13
185	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2013, 122, 2682-2682.	1.4	7
186	A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 542 1427-1427.	1.4	0
187	Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clinical Cancer Research, 2012, 18, 6723-6731.	7.0	100
188	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica, 2012, 97, 1736-1742.	3.5	65
189	Acute Lymphoblastic Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 858-914.	4.9	60
190	The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica, 2012, 97, 1225-1233.	3.5	19
191	Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood, 2012, 119, 55-63.	1.4	23
192	Phase 1 doseâ€ escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. British Journal of Haematology, 2012, 158, 198-207.	2.5	7
193	Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide. Clinical Cancer Research, 2011, 17, 5473-5480.	7.0	440
194	Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood, 2011, 117, 3302-3310.	1.4	77
195	Enzymatic Incorporation of Multiple Dyes for Increased Sensitivity in QDâ€FRET Sensing for DNA Methylation Detection. ChemBioChem, 2010, 11, 71-74.	2.6	33
196	Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. Current Opinion in Hematology, 2010, 17, 104-109.	2.5	7
197	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Research, 2010, 34, 877-882.	0.8	78
198	Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leukemia and Lymphoma, 2010, 51, 1711-1719.	1.3	72

#	ARTICLE	IF	CITATIONS
199	Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. <i>Epigenetics</i> , 2010, 5, 590-600.	2.7	42
200	DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay. <i>Methods</i> , 2010, 52, 237-241.	3.8	34
201	Statistically Significant Differences In Toxicities Between L- and PEG Asparaginase In Adult Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 2121-2121.	1.4	1
202	Abstract 3906: Twist regulates estrogen receptor expression in breast cancer. , 2010, , .		0
203	Relevance of Minor PIG-A Mutations In Acquired Aplastic Anemia and Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4433-4433.	1.4	0
204	MS-qFRET: A quantum dot-based method for analysis of DNA methylation. <i>Genome Research</i> , 2009, 19, 1455-1461.	5.5	126
205	Progressive Chromatin Repression and Promoter Methylation of <i>CTNNA1</i> Associated with Advanced Myeloid Malignancies. <i>Cancer Research</i> , 2009, 69, 8482-8490.	0.9	46
206	Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 315-325.	2.5	8
207	Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. <i>Blood</i> , 2009, 114, 2764-2773.	1.4	259
208	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. <i>Blood</i> , 2009, 114, 3448-3458.	1.4	292
209	A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group) Tj ETQq1 1 0.284314 rgBT /Overlo	0.7	1
210	Promoter methylation of <i>HIN-1</i> in the progression to esophageal squamous cancer. <i>Epigenetics</i> , 2008, 3, 336-341.	2.7	43
211	Tamoxifen-stimulated growth of breast cancer due to p21 loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 288-293.	7.1	86
212	Addition of Histone Deacetylase Inhibitors in Combination Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 1955-1956.	1.6	27
213	A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. <i>Blood</i> , 2007, 110, 1762-1769.	1.4	84
214	DNA Demethylating Agents and Histone Deacetylase Inhibitors in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 40-48.	2.0	31
215	Monitoring Methylation and Gene Expression in Cancer. , 2007, 383, 187-202.		1
216	Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML. , 2007, , 275-291.		0

#	ARTICLE	IF	CITATIONS
217	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. Blood, 2007, 110, 345-345.	1.4	2
218	a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.. Blood, 2007, 110, 2119-2119.	1.4	0
219	LKB1 Protein Expression in Human Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 146-153.	1.2	51
220	Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. Cancer Research, 2006, 66, 6361-6369.	0.9	470
221	Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacididine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.. Blood, 2006, 108, 517-517.	1.4	17
222	Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2 \pm Expression during Progression of Breast Cancer. Cancer Research, 2004, 64, 1611-1620.	0.9	67
223	New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Research, 2004, 6, 219-24.	5.0	83
224	Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. Cancer Treatment Reviews, 2004, 30, 303-307.	7.7	2
225	Plasma cell dyscrasia, Hodgkin lymphoma, HIV, and Kaposi sarcoma-associated herpesvirus. Current Opinion in Oncology, 2002, 14, 543-545.	2.4	9